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Abstract
Background: The Cancer of the Prostate Risk Assessment (CAPRA) score was designed and validated several times
to predict the biochemical recurrence-free survival after a radical prostatectomy. Our objectives were, first, to study
the clinical validity of the CAPRA score, and, second, to assess its clinical utility for stratified medicine from an
original patient-centered approach.
Methods: We proposed a meta-analysis based on a literature search using MEDLINE. Observed and predicted
biochemical-recurrence-free survivals were compared to assess the calibration of the CAPRA score. Discriminative
capacities were evaluated by estimating the summary time-dependent ROC curve. The clinical utility of the CAPRA score
was evaluated according to the following stratified decisions: active monitoring for low-risk patients, prostatectomy for
intermediate-risk patients, or radio-hormonal therapy for high risk patients. For this purpose, we assessed CAPRA’s clinical
utility in terms of its ability to maximize time-dependent utility functions (i.e. Quality-Adjusted Life-Years – QALYs).
Results: We identified 683 manuscripts and finally retained 9 studies. We reported good discriminative capacities with an
area under the SROCt curve at 0.73 [95%CI from 0.67 to 0.79], while graphical calibration seemed acceptable.
Nevertheless, we also described that the CAPRA score was unable to discriminate between the three medical alternatives,
i.e. it did not allow an increase in the number of life years in perfect health (QALYs) of patients with prostate cancer.
Conclusions: We confirmed the prognostic capacities of the CAPRA score. In contrast, we were not able to demonstrate
its clinical usefulness for stratified medicine from a patient-centered perspective. Our results also highlighted the
confusion between clinical validity and utility. This distinction should be better considered in order to develop predictive
tools useful in practice.
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Background
Prostate cancer (PC) is the most common cancer in men,
accounting for approximately 10% of all male cancer
deaths in economically developed countries [1]. In the long
term, many patients experience biochemical recurrence
(BCR), defined by an increase in prostate-specific antigen
(PSA) levels [2], which can also lead to cancer-specific
mortality [3]. Many developments have been made in pre-
dictive scoring systems [4–7] in order to avoid both
over-treatment of patients at low-risk of cancer recurrence
or death related to the cancer, and the under-treatment of
patients at high-risk.
Among these scores, the Cancer of the Prostate Risk
Assessment (CAPRA) score [8] was designed to predict
the pre-operative risk of BCR-free survival after a radical
prostatectomy (RP). RP represents the most widely per-
formed curative therapy for patients with localized PC
[9]. The CAPRA score is calculated from five variables
measured before prostatectomy: the PSA level, the Glea-
son score, the clinical T stage, the percentage of positive
prostate biopsies and the patient age at diagnosis. Meurs
et al. [10] performed a substantial meta-analysis of seven
studies and concluded that the CAPRA rule accurately
predicts BCR-free survival at 3 years.
Nevertheless, despite its good predictive capacities, the
clinical usefulness of the CAPRA score may be ques-
tioned. Firstly, the results of the meta-analysis of Meurs
et al. [10] mainly consisted in risk ratios between ex-
pected and observed numbers of events among three
CAPRA-based strata (0–2 for low risk, 3–5 for inter-
mediate risk, and 6–10 for high risk). The aim was to
evaluate the calibration compared to the initial study of
Cooperberg et al. [8]. But the discriminative capacities
were not evaluated. Secondly, the CAPRA thresholds
used to define the three strata were arbitrarily defined,
while the purpose of such a scoring system is to adapt
the medical management of patients regarding the strata
they belongs to. In two available online applications
related to the CAPRA computation [11, 12], the follow-
ing recommendations are proposed: routine surveillance
for low risk patients, localized treatment (surgery or radi-
ation alone, brachytherapy with or without external-beam
therapy) for intermediate-risk patients, hormonal therapy
or multimodal therapy (surgery with radiation, or radi-
ation therapy with hormonal therapy) for high-risk pa-
tients. However, to the best of our knowledge, no study
has assessed the clinical usefulness of the CAPRA score
for stratified medical decision making.
We hypothesized that the clinical usefulness depends
on its ability to bring benefits for patients by differentiat-
ing the following alternative therapies: the combined
radio-hormonal therapy (RHT) for patients at high-risk
of BCR, the RP for medium-risk patients and the active
monitoring (AM) for low-risk patients. In this paper,
from an update of the meta-analysis proposed by Meurs
et al. [10], our objectives were i) to study the clinical
validity of the CAPRA score, i.e. its prognostic capacities
both in terms of discrimination and calibration, and ii)
to evaluate its clinical utility, i.e. its usefulness for stratified
medical decision making from an original patient-centered
methodology that considers its corresponding benefits and
drawbacks [13].
Methods
Search strategy
We conducted a literature search using the MEDLINE
citation database to identify eligible studies by combin-
ing the following MeSH terms and keywords: “CAPRA
score”, “biochemical recurrence” and “prostate cancer”.
Since our analysis was an update of the meta-analysis of
Meurs et al. [10] published in March 2012, we restricted
our search after this date. No language restriction was
performed. Cross-referencing was applied to complete
the identification of other studies.
Study selection
Two investigators (Y.F and E.D) independently screened
the titles and abstracts of papers identified from the
literature search. Irrelevant articles were excluded. The
full text of each potentially relevant article was reviewed
and checked independently by two persons (Y.F and E.D
or H.M). Discrepancies between the three investigators
were resolved by consensus. As illustrated in Table 1, a
study was included in the analysis if it met the two fol-
lowing criteria: 1) prospective or retrospective study
conducted in PC patients having experienced RP, with
the preoperative CAPRA score as a predictor and
BCR-free survival as the endpoint; 2) study delivering
Hazard Ratios (HRs) and/or BCR-free survival curves
stratified according to CAPRA values. When the same
cohort was used in several publications, only the most
recent study was selected if it contained the statistical
indicators necessary for our meta-analysis.
Data extraction
From the eligible studies, two independent investigators
(H.M and Y.F) collected the data independently. For
each study, the following characteristics were collected:
Table 1 PICOS table related to the selection of the papers
Patient population Patients with Prostate Cancer
with available CAPRA score
Intervention Having a radical prostatectomy
Comparison intervention With or without control group
Outcomes Biochemical-recurrence-free survival
Study type Prospective or retrospective study
presenting hazard ratio and/or
survival curves
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first author, year of publication, country, period of recruit-
ment, duration of follow-up, study setting and design,
sample size, age, reported outcomes, association between
CAPRA and BCR-free survival (HRs and 95%CI), number
of patients in each CAPRA-based strata, presence of
survival curves and the corresponding number of at-risk
patients, and the Harrell’s concordance index (C-index).
Any disagreement was resolved by consensus. All statistical
analyses were performed using the 3.1.1 version of the R
software [14]. The survival probabilities were extracted
from a digitalized picture by using the R packages ReadI-
mages and digitize [15]. Many papers do not provide the
number of at-risk patients over time, so we applied the
method proposed by Parmar et al. [16] in order to obtain
estimations.
Assessing clinical validity
The association between the CAPRA score and BCR-free
survival was evaluated by estimating pooled HRs which
compared the high-risk category (CAPRA ≥6) and the
intermediate-risk category (2 < CAPRA < 6) to the low-risk
category of the CAPRA score (CAPRA≤2). When it was
available, we used the category from 0 to 2 as the low-risk
category, or otherwise we used the category 0 to 1. Col-
lected HRs were pooled by applying a random-effects
model and the DerSimonian-Laird estimator [17] (R pack-
age metaphor). Sensitivity analysis was conducted by elim-
inating a single study one-at-a-time. Publication bias was
evaluated statistically by the Kendall’s tau and the Egger’s
linear regression test of the intercept [18]. Heterogeneity
between studies was assessed by Cochrane Q and I2 statis-
tics [19] (R package meta). We also investigated potential
heterogeneity by comparing pooled HRs stratified given
possible heterogeneity factors: effective size, inclusion
period and the geographic origin of the study. The out-
come definition appeared homogeneous between studies,
so there was no reason to test it as a heterogeneity factor.
Pooled survival curves per CAPRA-based strata were
estimated by the distribution-free approach with random
effects proposed by Combescure et al. [20]. The calibra-
tion was assessed graphically by comparing the pooled
survival curves for each CAPRA strata to those esti-
mated in the original paper by Cooperberg [8]. The
discrimination capacities at 5-years post-RP were evalu-
ated using the time-dependent summary ROC (SROCt)
curves [21].
Assessing clinical utility
We endorse a patient-centered approach to medical de-
cision making by defining the clinical utility of a decision
in terms of the expected Quality-Adjusted Life-Years
(QALYs) it brings. QALYs combine into a single index,
information about the length of life and health-related
quality of life. They are computed by weighting each
period of life (usually a year) by a utility score such that
a score of zero indicates death and a score of one stands
for perfect health [22]. The utility scores represent the
individuals’ preferences over health states such that a
higher score indicates a more preferred health state. Al-
though QALYs were primarily designed for the conduct
of economic evaluation, their composite nature may also
be useful to inform clinical decision making [23].
More precisely, as demonstrated by Dantan et al. [24],
the expected number of QALYs resulting from the use
of a prognostic marker’s threshold to decide between
two alternative therapies can be determined as follows.
Let T, X and κ be the time-to-failure, the baseline prog-
nostic marker under investigation to drive the treatment
allocation, and a given threshold of X. Let D(τ) be the indi-
cator of failure such that D(τ) = 1 if it occurs before the
forecast horizon time τ, and D(τ) = 0 otherwise. Patient
profiles may therefore be distinguished by combining their
two possible initial strata according the marker X (X > κ or
X ≤ κ) and the two possible outcomes (D(τ) = 1 or D(τ) =
0) over the time horizon under consideration. The optimal
threshold κ∗ can be estimated as the threshold that maxi-
mizes the expected number of QALYs:
X
g∈ X>κ;X ≤κf gP gð Þ ug;0E min T ; τð Þjgð Þ þ ug;1 τ−E min T ; τð Þjgð Þð Þ
 
ð1Þ
where P(g) is the proportion of patients in strata g,
E(min(T, τ)| g) is the Restricted Mean Survival Time
(RMST) up to time τ in the strata g, i.e. the average sur-
vival time when patients are followed up to τ [25] and
(ug, 0, ug, 1) are the utility scores for health states D(τ) =
0 and D(τ) = 1 in the strata g. Therefore, calculating
QALYs requires information about i) the survival prob-
abilities and ii) the utility scores corresponding to the
relevant health states.
Survival estimation
The RMST, E(min(T, τ)| g), which need to be estimated
for all possible thresholds κ of the marker X, was esti-
mated as the area under the corresponding survival
curve S(t| g) until time τ. We used the methodology pre-
viously proposed by Combescure et al. [21]. Survival
probability at time t given strata g is defined as follows
and numerically calculated using the 30-points Gauss–
Legendre quadrature:
S tjg ¼ X > κf gð Þ ¼
R∞
κ exp −
R t
0 Eν λ ujx; νð Þ½ du
 
E f xjωð Þ½ dx
R∞
κ E f xjωð Þ½ dx
ð2Þ
In eq. 2, the distribution of the marker X, f(x|ωi), is esti-
mated according to a log-normal distribution interval-
truncated in-between 0 and 10 (i.e. the CAPRA range),
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ωi~Ν(0, σω) is a random effect of the mean for the study i
and σω its standard error. The instantaneous risk function
of BCR, namely λ(t| x,ωi), is estimated according to a flex-
ible piecewise constant risk function:
λ tjx; νið Þ ¼ exp νi þ
XL
l¼0 βl;1 þ βl;2
 
 1 t > τlf g
h i
ð3Þ
where (βl, 1, βl, 2) are the regression coefficients specific
to the interval l ∈ {1,…, L} (L being the number of time
intervals), υi~Ν(0, συ) is a random effect of the mean for
the study i and συ its standard error. To obtain f(x| ωi)
and λ(t| x, νi), we used the R package nlme based on the
maximization of the restricted log-likelihood.
The survival probabilities were estimated from articles
including patients with RP. For a stratified decision, we
considered alternative therapies (AM and RHT) that will
impact the survival probabilities. We studied several
plausible scenarios in terms of decreasing length of life:
a RMST loss of 10% at 5 years for AM versus RP [26]
and in-between 20 to 40% for RP versus RHT [27–29].
Utility scores determination
Following Koerber et al. [30], we assumed that the base-
line utility for PC patients can be approximated by an
age-adjusted utility score of the general population. This
baseline utility is then combined with the utilities of
various health conditions (symptoms of prostate cancer
and treatments) using a multiplicative model. Although
there is no consensus about the appropriate method that
should be used, there is recent evidence in favor of the
multiplicative model for combining scores for health
states compared to the alternative model [31, 32].
The event predicted by the CAPRA score is the first
failure between disease progression (biochemical recur-
rence or distant metastasis) and death. For each treat-
ment group (RP, AM, RHT), we calculated the expected
utility before this event as the product of age-adjusted
baseline utility and the utilities of symptoms associated
with the treatment group weighted by their repartition.
We calculated the corresponding utility after the event as
the product of utility before the event and the utilities of
disease progression or death weighted by their repartition.
Supplementary information on the precise method of util-
ity calculation is provided in the Additional file 1.
Numerous studies have published utility scores for
health states related to PC assessed using various methods
[33–38]. We chose the utility scores estimated by Stewart
et al. [37] on a sample of patients aged 60 (the mean/me-
dian patient age in the included study in our meta-analysis
centered around this value, Table 3) and over. These
scores were deemed the most suitable for our study be-
cause they were directly assessed from patients and they
were reported for both single symptoms and for comorbid
health conditions. The raw utility scores and their sources
are reported in Table 2. Since there was no utility value
for active monitoring in the study proposed by Stewart et
al. [37], we arbitrarily chose a score of 0.98 which seems
in line with recent evidence suggesting that men undergo-
ing active surveillance have high utility scores [33]. Repar-
tition of each symptom and subtype of event given the
treatment group are based on a literature search and are
detailed in the Additional file 1.
Results
Description of the selected studies
A flowchart of the selected studies is presented in Fig. 1.
We identified 683 manuscripts of which only 12 under-
went full text review. No additional study was identified
by cross-referencing. We also considered the 8 valid-
ation studies included in the meta-analysis of Meurs et
al. [10] Among these 20 articles, we finally retained 9
studies: the original study of Cooperberg et al. [8], 5
studies [39–43] published between 2005 and 2012 and
selected by Meurs et al. [10], and 3 additional studies
[44–46] published more recently. The study proposed by
Tamblyn et al. [47] in 2011, selected by Meurs et al. [10],
was excluded because the authors did not present
BCR-free survival curves according to CAPRA values.
The work of Lughezzani et al. [48] in 2010, selected by
Meurs et al. [10], was excluded because the same popu-
lation with a longer follow-up was used by Budaus et al.
[44] in 2012. Furthermore, the latter included all the
statistical indicators necessary for our meta-analysis.
Table 2 Sources and estimation of raw utility scoresa
Value Source
Baseline utility value for age 60 0.84 Ara and Brazier [32]
Sexual dysfunction 0.89 Stewart et al. [37]
Sexual dysfunction and urinary
incontinence
0.78
Impotence and bowel dysfunction 0.57
Impotence, urinary incontinence,
and bowel dysfunction
0.45
Local disease progression 0.67
Metastatic cancer 0.25
Active monitoring 0.98 Authors’ assumption
aThe table reports ‘raw’ scores. The final scores used in our calculations were obtained
by combining the baseline score with these raw scores using a multiplicative model.
For instance, the final score for sexual dysfunction is obtained by multiplying the
score in Stewart et al. by our baseline utility value (see the Additional file 1)
Finally, for patients alive without BCR, the utility scores were estimated at 0.79
under AM, 0.76 under RP and 0.72 under RHT. By merging the utilities related
to the combined event (disease progression or death), the expected utility
scores after the treatment failure were assessed at 0.34 under AM, 0.24 under
RP and 0.20 under RHT. A sensitivity analysis was carried out by varying the
patient age between 55 and 75 years. The conclusions of the analyses were
unchanged (data not shown)
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The main features of the 9 eligible studies (15,908
patients) are summarized in Table 3. All studies
were based on prospective cohorts of patients
treated by RP. The sample size per study ranged
from 115 to 6737 patients. The mean age ranged
from 58.0 to 66.4 years. Four studies were conducted
Fig. 1 The flowchart describing the 9 selected articles of the meta-analysis
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in the USA, 2 in Germany, 2 in Japan, 1 in Korea
and 1 in Australia.
Association between the CAPRA score and BCR-free
survival
The 9 retained articles [8, 39–46] provided HRs or sur-
vival curves (from which one can re-estimate the HRs)
according to CAPRA-based strata. As illustrated in Fig. 2,
the pooled HR of patients at high-risk (CAPRA≥6) ver-
sus those at low-risk (CAPRA≤2) was 10.65 [95%CI from
6.63 to 17.10]. The HR was 3.29 [95%CI from 2.18 to
4.96] for patients at intermediate-risk compared to those
at low-risk. The analysis indicated a non-significant pub-
lication bias (Kendall’s test statistic = 0.28, p = 0.3585 for
the two group comparisons; Egger’s tests = 1.06, p =
0.210 for high versus low risk groups; Egger’s tests =
0.46, p = 0.6474 for intermediate versus low risk groups)
and a large heterogeneity among the studies (Cochrane
Q= 63.16, p < 0.0001 for high versus low risk groups;
Cochrane Q= 33.08, p < 0.0001 for intermediate versus low
risk groups; I2 = 91.18 and 84.25% for the 2 respective
group comparisons). As illustrated in Table 4, one cannot
identify any significant reason to explain this heterogeneity.
Clinical validity of the CAPRA score up to five years post-
prostatectomy
The area under the SROCt curve (AUC) at 5 years
post-prostatectomy was 0.73 [95%CI from 0.67 to 0.79].
The AUCs for each study ranged from 0.67 [95%CI from
0.61 to 0.73] to 0.76 [95%CI from 0.71 to 0.81], indicating
acceptable discriminative capacities of the CAPRA score.
Seven validation studies [39–41, 44–46] with survival
curves according to the 3 CAPRA-based strata were
considered. As illustrated in Fig. 3, patients at low-risk
have 80.8% chance [95%CI from 70.8 to 86.6] of not suf-
fering a BCR or a death within the 5 years post-RP. In
contrast, patients at high-risk have a 73.2% risk [95%CI
from 61.7 to 86.6] of suffering a BCR or death within 5
years post-RP. Note that in the original study, the 5-year
BCR-free survival probabilities in low-, intermediate-,
and high-risk strata were 84.7, 62.7 and 21.8%, respect-
ively (Fig. 3, 95%CI were not provided). In comparison
to the pooled survival curves, the calibration of the
CAPRA score appeared acceptable.
Clinical utility of the CAPRA score for deciding AM instead
of RP
Only patients with a CAPRA score strictly lower than 6
were included since AM is not proposed to high-risk pa-
tients (i.e. CAPRA≥6). The maximum number of QALYs
was obtained when RP is proposed to all patients. In
other words, for all the CAPRA thresholds in-between 1
and 5, the expected gain in terms of QoL related to AM
was insufficient to balance the associated decrease in the
BCR-free survival. More precisely, the mean number of
QALYs, i.e. the expected equivalent of years lived in per-
fect health, was 42.4 months if all patients are treated by
RP. In contrast, when patients with a CAPRA score
lower than 2 (the usual threshold separating low and
intermediate-risk strata) are treated by AM and the
other ones by RP, the mean number of QALYs was 41.7
months. Therefore, for a cohort of 100 patients, this
stratification was associated with an expected loss of 70
months in perfect health compared to treating all pa-
tients by RP.
Clinical utility of the CAPRA score for deciding RHT
instead of RP
Only patients with a CAPRA score strictly higher than 2
were included since treatment by RHT is not proposed
to low-risk patients (i.e. CAPRA≤2). The maximum
number of QALYs was obtained by proposing RHT to
all patients: 41.6 months in perfect health state. Regard-
less of the CAPRA threshold, all the stratified medical
decision making resulted in lower numbers of QALYs.
For instance, by using the usual CAPRA-based stratifica-
tion (CAPRA< 6 for intermediate risk strata versus
CAPRA≥6 for high risk strata), we estimated that the
mean number of life-years in perfect health was 39.6
months. Therefore, for a cohort of 100 patients, the use
of CAPRA threshold at 6 for stratifying the medical de-
cision between RP and RHT would have been associated
with a loss of 200 months in perfect health state com-
pared to treating all patients by RHT.
Discussion
Prognostic tools are essential in PC to adapt the medical
management regarding the risk-level of patients [49–51].
In this context, our meta-analysis aimed to precisely de-
scribe the usefulness of the CAPRA score for stratified
medicine.
Our results were obtained by analyzing 9 studies. In
agreement with the literature and by considering the
three usual CAPRA-based strata, we validated the asso-
ciation between the CAPRA score and the BCR-free sur-
vival (HR intermediate versus low = 3.29 [95%CI from
2.18 to 4.96] and HR high versus low = 10.65 [95%CI
from 6.63 to 17.10]). We additionally described the
CAPRA score as a marker with a robust capacity to dis-
criminate BCR or dead patients at 5-year post-RP from
alive patients without BCR at this time (AUC = 0.73
[95%CI from 0.67 to 0.79]). In terms of calibration, we
also reported acceptable properties up to 5 years
post-RP. However, despite this validity, we were unable to
demonstrate the clinical utility of the CAPRA score in
regards to the following stratified medical decision mak-
ing: AM for low-risk patients, RP for intermediate-risk pa-
tients and RHT for high-risk patients.
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Our study highlights the important confusion between
clinical validity and utility. Indeed, even if the relevance
of stratified medical decision making partially depends
on the prognostic capacities of a biomarker or a scoring
system, other dimensions are also important to consider,
in particular the consequences of both quantity and
quality of life, and on trade-offs between them. Several
recent studies discussed the importance of considering
Fig. 2 The forest plots for pooled hazard ratios. a) High-risk group (CAPRA ≥6) versus the low-risk group (CAPRA ≤2). b) Intermediate-risk group
(2 < CAPRA < 6) versus the low-risk group (CAPRA ≤2)
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these two dimensions [23, 52, 53]. We also believe that
better understanding of these dimensions in studies re-
lated to predictive biomarkers or scoring systems for
stratified medicine can improve the transfer of such
tools into clinical practice.
From a methodological point of view, the large major-
ity of papers in stratified medicine have focused on the
evaluation of prognostic capacities, mainly by estimating
area under ROC curves. In contrast, our results illustrate
the necessity for a paradigm shift towards the evaluation
of clinical usefulness, by estimating time-dependent util-
ity function for instance [24].
Alternative decision-making approaches have been
proposed that incorporate the consequences of clinical
choices when assessing the usefulness of diagnostic tests
or of prediction models. For instance, the widely used
Decision Curve Analysis (DCA) computes the net bene-
fit of a medical decision as the difference between its
benefits and harms [54]. In DCA, the benefits and harms
are obtained by asking the physicians for the probability
threshold, i.e. the rate at which the patients are willing
to trade-off between the harms and the benefits of a
medical decision. A decision curve then plots the net
benefit of a decision against the net benefits of “treating
all” or “treating none” for the various possible values of
the probability threshold. Although DCA may be easier
to implement compared to our QALY-based approach,
the two approaches may not lead to similar conclusions
as they differ importantly. DCA relies on the physicians’
prediction about the value of outcome [55], whereas pa-
tients’ utility scores come from those experiencing (of
having experienced) the health conditions under consid-
eration. There is no guarantee that the physicians’ judg-
ments accurately reflect the views of the patients.
Several studies found differences between the prefer-
ences of the patients and physicians for various condi-
tions [56], especially in prostate cancer [57]. Although
our QALY-based approach may be more in line with pa-
tients’ preferences than DCA, the assessment of utility
scores raises practical difficulties and published utility
values are quite heterogeneous. Nevertheless, we believe
that addressing these difficulties in future research may
offer a more promising way to develop patient-centered
approaches of medical decision making rather than rely-
ing solely on physicians’ judgements.
It appears important to underline that the concept of
clinical utility is multidimensional. It cannot be summa-
rized into a single measure, whether it is QALYs or
DCA. As explained by Smart [13], one can judge the
concept of utility by using four components: appropriate,
accessible, practicable, and acceptable. QALYs or DCA
mainly concern the first one.
Our study nevertheless has some limitations. First, we
identified a significant heterogeneity between the studies
retained in our meta-analysis. We explored the possible
causes of this heterogeneity, but we were not able to
identify any significant reason. Second, the estimations
of the SROCt curve [21] and the time-dependent utility
function [24] both depend on many parametric assump-
tions. As with any meta-analysis on aggregated data, the
corresponding limitation being listed by Lyman and
Kuderer [58], it would have been preferable to collect
the individual data necessary for such an analysis. To
limit this issue, we have also non-parametrically adapted
the two estimators after having reconstructed individual
data (data not shown). The corresponding results were
similar to the ones described in the main text. Third, nu-
merous hypotheses are required to define the potential
consequences of each alternative treatment (AM, RP
and RHT) in terms of both quantity and quality of life.
We attempted to be as realistic as possible in defining
these hypotheses on data recently published in this field.
Fourth, we did not study RP (for medium-risk patients)
and RP + RHT (for high-risk patients). The reason is that
it would require information about the removed tumor
that is not included in the CAPRA score. Cooperberg et
al. proposed the CAPRA-S score [59], as an extension of
the CAPRA score that consider information about the
tumor (surgical margin, seminal vesicle invasion, extra-
capsular extension, lymph node invasion). However, an
analysis based on the CAPRA-S would be beyond the
scope of our paper. Fifth, we separately investigated the
discriminative capacities and the calibration of the
CAPRA score. It would have been relevant to also esti-
mate the global prognostic performance of the score, for
instance by estimating the Index of Prognostic Accuracy,
Table 4 Investigation of the heterogeneity of the HRs according to CAPRA-based strata
Number of studies
per subgroup
Pooled HR (High versus
Low) per subgroup
p-value Pooled HR (Intermediate
versus Low) per subgroup
p-value
Effective size > 1000: 5
≤ 1000: 4
14.60 [7.24–29.43]
8.13 [4.13–16.01]
0.240 4.45 [2.32–8.54]
2.35 [1.59–3.47]
0.098
Inclusion period Inclusion start ≥1999: 3
Inclusion start < 1999: 6
10.37 [5.00–21.49]
11.78 [5.83–23.80]
0.804 2.78 [1.83–4.24]
3.78 [2.04–7.00]
0.419
Geographic origin American: 4
Other: 5
13.37 [9.25–19.32]
9.75 [4.02–23.60]
0.518 3.34 [2.41–4.61]
3.39 [1.48–7.77]
0.971
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Fig. 3 Calibration plots. a The pooled survival curves according to CAPRA-based strata compared to the survival curves from the original study.
b Pooled survival versus observed survival in the original study
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as recently proposed by Kattan and Gerds [60]. Never-
theless, the corresponding pooled estimation from a
published study does not exist to our knowledge and
constitutes interesting perspective for future methodo-
logical developments.
Conclusions
Our study validated the prognostic capacities of the
CAPRA score. Nevertheless, based on a QALYs maximi
zation approach, our results challenged its clinical use-
fulness to beneficially stratify patients between three
common therapeutic strategies: RHT for high-risk, RP
for intermediate-risk, and AM for low-risk patients. Our
results highlight the confusion between prognostic cap-
acities and clinical usefulness. It calls for a better consid-
eration of this distinction and for a paradigm shift from
clinical validity to clinical utility in studies related to
stratified medicine.
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